Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma-Reference-Cited by-同舟云学术

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma

Published:2023-11-10 Issue:3 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Jang Albert¹²^ORCID,Lichterman Jake N.³^ORCID,Zhong Jeffrey Y.²,Shoag Jonathan E.⁴,Garcia Jorge A.²,Zhang Tian³,Barata Pedro C.²^ORCID

Affiliation:

1. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA

2. Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA

3. Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

4. Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2276629

Reference126 articles.

1. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

2. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?

3. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

4. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

5. Nektar and Bristol Myers Squibb announce update on clinical development program for bempegaldesleukin (BEMPEG) in combination with opdivo (nivolumab). Bristol Myers Squibb; 2022. https://news.bms.com/news/details/2022/Nektar-and-Bristol-Myers-Squibb-Announce-Update-on-Clinical-Development-Program-for-Bempegaldesleukin-BEMPEG-in-Combination-with-Opdivo-nivolumab/default.aspx#:~:text=(PRINCETON%2C%20N.J.%2C%20%26%20SAN nivolumab)%20in%20renal%20cell%20carcinoma%20(.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of RNA-binding protein hnRNP C targeting the 3’UTR of the TAP-associated glycoprotein tapasin in melanoma;OncoImmunology;2024-06-27

2. Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma;Heliyon;2024-04